[Combined effect of HO-221 with various antitumor agents against L 1210 leukemia]. 1991

T Nakajima, and H Masuda, and T Okamoto, and M Watanabe, and K Yokoyama, and N Yamada, and S Tsukagoshi, and T Taguchi
Research Division, Green Cross Corporation.

Combined effect of N-[4-(5-bromo-2-pyrimidinyloxy)-3-chlorophenyl]-N'-(2-nitrobenzoyl ) urea, HO-221, with various antitumor agents was studied using L 1210 leukemia in vivo and in vitro. Ten anticancer drugs were chosen from alkylating agents, antitumor antibiotics, antimetabolites and plant alkaloids each. The combined effect was assessed by comparing ILS (increase of life span) in the combined group with the sum of ILS of each single agent. Synergistic effect was considered to exist if ILS of the combination-treatment group exceeds the sum of those in 2 single-treatment groups. The two-drug combination of HO-221 with cyclophosphamide (CPA), adriamycin (ADM), mitomycin C (MMC), vindesine (VDS), vincristine (VCR) or etoposide showed remarkable synergistic effects with 60-days survivors. However, the combination chemotherapy with antimetabolites, 5-fluorouracil (5-FU) and methotrexate (MTX) showed competitive effects. Moreover, the synergistic cytocidal effect in vitro by the clonogenic assay was observed in combination of HO-221 with the same drug using in vivo test. The present results indicate that HO-221 seems to be a useful antitumor agent in combination chemotherapy.

UI MeSH Term Description Entries
D007939 Leukemia L1210 An experimental LYMPHOCYTIC LEUKEMIA of mice. Leukemia L 1210,L 1210, Leukemia,L1210, Leukemia
D008297 Male Males
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D008811 Mice, Inbred DBA An inbred strain of mouse. Specific substrains are used in a variety of areas of BIOMEDICAL RESEARCH such as DBA/1J, which is used as a model for RHEUMATOID ARTHRITIS. Mice, DBA,Mouse, DBA,Mouse, Inbred DBA,DBA Mice,DBA Mice, Inbred,DBA Mouse,DBA Mouse, Inbred,Inbred DBA Mice,Inbred DBA Mouse
D009578 Nitrobenzenes BENZENE derivatives carrying nitro group substituents.
D004357 Drug Synergism The action of a drug in promoting or enhancing the effectiveness of another drug. Drug Potentiation,Drug Augmentation,Augmentation, Drug,Augmentations, Drug,Drug Augmentations,Drug Potentiations,Drug Synergisms,Potentiation, Drug,Potentiations, Drug,Synergism, Drug,Synergisms, Drug
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D000971 Antineoplastic Combined Chemotherapy Protocols The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form. Anticancer Drug Combinations,Antineoplastic Agents, Combined,Antineoplastic Chemotherapy Protocols,Antineoplastic Drug Combinations,Cancer Chemotherapy Protocols,Chemotherapy Protocols, Antineoplastic,Drug Combinations, Antineoplastic,Antineoplastic Combined Chemotherapy Regimens,Combined Antineoplastic Agents,Agent, Combined Antineoplastic,Agents, Combined Antineoplastic,Anticancer Drug Combination,Antineoplastic Agent, Combined,Antineoplastic Chemotherapy Protocol,Antineoplastic Drug Combination,Cancer Chemotherapy Protocol,Chemotherapy Protocol, Antineoplastic,Chemotherapy Protocol, Cancer,Chemotherapy Protocols, Cancer,Combinations, Antineoplastic Drug,Combined Antineoplastic Agent,Drug Combination, Anticancer,Drug Combination, Antineoplastic,Drug Combinations, Anticancer,Protocol, Antineoplastic Chemotherapy,Protocol, Cancer Chemotherapy,Protocols, Antineoplastic Chemotherapy,Protocols, Cancer Chemotherapy
D001549 Benzamides BENZOIC ACID amides.

Related Publications

T Nakajima, and H Masuda, and T Okamoto, and M Watanabe, and K Yokoyama, and N Yamada, and S Tsukagoshi, and T Taguchi
October 1977, Gan,
T Nakajima, and H Masuda, and T Okamoto, and M Watanabe, and K Yokoyama, and N Yamada, and S Tsukagoshi, and T Taguchi
January 1965, Antimicrobial agents and chemotherapy,
T Nakajima, and H Masuda, and T Okamoto, and M Watanabe, and K Yokoyama, and N Yamada, and S Tsukagoshi, and T Taguchi
March 1991, Gan to kagaku ryoho. Cancer & chemotherapy,
T Nakajima, and H Masuda, and T Okamoto, and M Watanabe, and K Yokoyama, and N Yamada, and S Tsukagoshi, and T Taguchi
December 1981, Journal of pharmacobio-dynamics,
T Nakajima, and H Masuda, and T Okamoto, and M Watanabe, and K Yokoyama, and N Yamada, and S Tsukagoshi, and T Taguchi
July 1982, Journal of pharmacobio-dynamics,
T Nakajima, and H Masuda, and T Okamoto, and M Watanabe, and K Yokoyama, and N Yamada, and S Tsukagoshi, and T Taguchi
June 1989, Gan to kagaku ryoho. Cancer & chemotherapy,
T Nakajima, and H Masuda, and T Okamoto, and M Watanabe, and K Yokoyama, and N Yamada, and S Tsukagoshi, and T Taguchi
October 1980, Journal of medicinal chemistry,
T Nakajima, and H Masuda, and T Okamoto, and M Watanabe, and K Yokoyama, and N Yamada, and S Tsukagoshi, and T Taguchi
November 1973, Comptes rendus hebdomadaires des seances de l'Academie des sciences. Serie D: Sciences naturelles,
T Nakajima, and H Masuda, and T Okamoto, and M Watanabe, and K Yokoyama, and N Yamada, and S Tsukagoshi, and T Taguchi
October 1980, Research communications in chemical pathology and pharmacology,
T Nakajima, and H Masuda, and T Okamoto, and M Watanabe, and K Yokoyama, and N Yamada, and S Tsukagoshi, and T Taguchi
October 1970, Gan,
Copied contents to your clipboard!